Press release
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE)1,2 FRIENDSWOOD, Texas--(BUSINESS
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nCastle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE)1,2\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the latest American Gastroenterological Association (AGA) clinical practice guideline recognized that not all patients with non-dysplastic BE (NDBE) are at low risk of developing esophageal cancer. The guideline acknowledges the role that tissue-based biomarkers, including the tissue systems pathology test (TissueCypher, also known as TSP-9), can play in identifying high-risk NDBE patients who may benefit from endoscopic eradication therapy (EET) to prevent disease progression.3\n\n\nBE with high-risk features can often be effectively treated with EET, such as ablation, which involves either burning or freezing the abnormal esophageal lining. However, the ability to reliably identify patients at increased risk of progression is crucial to avoid missing patients who develop esophageal cancer as well as limiting the over treatment of patients who have a lower risk of progression. Studies have shown that TissueCypher is an independent predictor of progression in patients with BE. Further, a pooled analysis of clinical data from the Mayo Clinic showed that patients with NDBE, traditionally deemed to be at a lower risk of advancing to esophageal cancer, who receive TissueCypher high-risk scores, are 18-times more likely to progress than patients with low-risk scores.1\n\n\nIn the recently published AGA guideline, the expert panel of authors acknowledge the role that tissue-based biomarkers (particularly aberrant p53 or TissueCypher, alone or in combination with clinical and endoscopic characteristics) can play in stratifying the large pool of patients with NDBE to help identity those at high risk of progression for consideration of treatment with EET at an early, precancerous stage.\n\n\n“We are pleased that the AGA has recognized that there is a high-risk subset of NDBE patients who may benefit from early intervention with EET and importantly, have acknowledged that tissue-based biomarker testing can help identify these patients,” said Emmanuel Gorospe, M.D., board-certified gastroenterologist and GI medical director at Castle Bio...